Ouverture Paris du rouge mais au-dessus des 7.000 points... - Fortuneo
| ALQGC Stock | EUR 0.07 0.0001 0.14% |
Slightly above 56% of Quantum Genomics' investor base is looking to short. The analysis of current outlook of investing in Quantum Genomics SA suggests that many traders are alarmed regarding Quantum Genomics' prospects. Quantum Genomics' investing sentiment overview a quick insight into current market opportunities from investing in Quantum Genomics SA. Many technical investors use Quantum Genomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Quantum |
Ouverture Paris du rouge mais au-dessus des 7.000 points... Fortuneo
Read at news.google.com
 |
Quantum Genomics Fundamental Analysis
We analyze Quantum Genomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quantum Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quantum Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Quantum Genomics is rated fourth in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Quantum Genomics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Quantum Genomics stock to make a market-neutral strategy. Peer analysis of Quantum Genomics could also be used in its relative valuation, which is a method of valuing Quantum Genomics by comparing valuation metrics with similar companies.
Peers
Quantum Genomics Related Equities
| ALBIO | Biosynex | 2.36 | ||||
| ALERS | Eurobio Scientific | 0.59 | ||||
| OSE | OSE Pharma | 4.40 | ||||
| ALKAL | Kalray SA | 14.29 |
Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.